6 Results for "

interstitial renal fibrosis

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "interstitial renal fibrosis" in MCE Product Catalog:

18
18 Publications Verification
Cat. No.: HY-P0299
CAS No.: 283609-79-0
Target:  

TGF-β Receptor

Research Areas:  

Cancer

LSKL, Inhibitor of Thrombospondin (TSP-1) is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) can readily crosse the blood-brain barrier .
loading...
    loading...
18
18 Publications Verification
Cat. No.: HY-P0299A
CAS No.: 2828433-17-4
Target:  

TGF-β Receptor

Research Areas:  

Cancer

LSKL, Inhibitor of Thrombospondin (TSP-1) TFA is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) TFA can readily crosse the blood-brain barrier .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N2013
CAS No.: 13395-02-3
Synonyms: Aristololactam; Aristolactam
Aristolactam I is an AQP1 inhibitor and Aristolochic acid I metabolite. Aristolactam I can be isolated from Aristolochia plants. Aristolactam I downregulates Twist1 expression, increases E-cadherin expression, and activates the TGF-β/Smad signaling pathway. Aristolactam I has anticancer activity against breast cancer. Aristolactam I is nephrotoxic. Aristolactam I is mainly used in the study of breast cancer and kidney diseases such as renal interstitial fibrosis .
loading...
    loading...
Cat. No.: HY-N7055
CAS No.: 2752-99-0
Synonyms: Trierucoylglycerol
Trierucin (Trierucoylglycerol) is a triester formed by glycerol and erucic acid, which serves as an occlusive skin conditioning agent and non-aqueous thickener in cosmetics. Long-term feeding of Trierucin to rats induces chronic toxicities such as cardiac lipid deposition and fibrosis .
loading...
    loading...
Cat. No.: HY-N2013R
CAS No.: 13395-02-3
Synonyms: Aristololactam (Standard); Aristolactam (Standard)
Aristolactam I (Standard) is the analytical standard of Aristolactam I. This product is intended for research and analytical applications. Aristolactam I is an AQP1 inhibitor and Aristolochic acid I metabolite. Aristolactam I can be isolated from Aristolochia plants. Aristolactam I downregulates Twist1 expression, increases E-cadherin expression, and activates the TGF-β/Smad signaling pathway. Aristolactam I has anticancer activity against breast cancer. Aristolactam I is nephrotoxic. Aristolactam I is mainly used in the study of breast cancer and kidney diseases such as renal interstitial fibrosis .
loading...
    loading...
Cat. No.: HY-189141
Research Areas:  

Endocrinology

HIPK2-IN-2 is an orally active and selective HIPK2 inhibitor with an IC50 of 0.36 μM against HIPK2. HIPK2-IN-2 reduces HIPK2 protein expression levels. HIPK2-IN-2 inhibits the proliferation and migration of renal interstitial fibroblasts, alleviates renal tubular injury and collagen deposition, and suppresses TGF-β/Smad3-mediated profibrotic signaling pathways as well as TNF-α/NF-κB-mediated inflammatory signaling pathways in renal cells. HIPK2-IN-2 is used for the study of chronic kidney disease-associated renal fibrosis .
loading...
    loading...